These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 9113065)
1. Amido analogs of mitoxantrone: physico-chemical properties, molecular modeling, cellular effects and antineoplastic potential. Zagotto G; Moro S; Uriarte E; Ferrazzi E; Palù G; Palumbo M Anticancer Drug Des; 1997 Mar; 12(2):99-112. PubMed ID: 9113065 [TBL] [Abstract][Full Text] [Related]
2. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. Gatto B; Zagotto G; Sissi C; Cera C; Uriarte E; Palù G; Capranico G; Palumbo M J Med Chem; 1996 Aug; 39(16):3114-22. PubMed ID: 8759632 [TBL] [Abstract][Full Text] [Related]
3. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects. De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. De Isabella P; Palumbo M; Sissi C; Capranico G; Carenini N; Menta E; Oliva A; Spinelli S; Krapcho AP; Giuliani FC Mol Pharmacol; 1995 Jul; 48(1):30-8. PubMed ID: 7623772 [TBL] [Abstract][Full Text] [Related]
5. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Sissi C; Moro S; Richter S; Gatto B; Menta E; Spinelli S; Krapcho AP; Zunino F; Palumbo M Mol Pharmacol; 2001 Jan; 59(1):96-103. PubMed ID: 11125029 [TBL] [Abstract][Full Text] [Related]
6. New anthracenedione derivatives with improved biological activity by virtue of stable drug-DNA adduct formation. Mansour OC; Evison BJ; Sleebs BE; Watson KG; Nudelman A; Rephaeli A; Buck DP; Collins JG; Bilardi RA; Phillips DR; Cutts SM J Med Chem; 2010 Oct; 53(19):6851-66. PubMed ID: 20860366 [TBL] [Abstract][Full Text] [Related]
7. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation. Stefańska B; Dzieduszycka M; Bontemps-Gracz MM; Borowski E; Martelli S; Supino R; Pratesi G; De Cesare M; Zunino F; Kuśnierczyk H; Radzikowski C J Med Chem; 1999 Sep; 42(18):3494-501. PubMed ID: 10479282 [TBL] [Abstract][Full Text] [Related]
8. Anthracenedione-methionine conjugates are novel topoisomerase II-targeting anticancer agents with favorable drug resistance profiles. Lee CH; Hsieh MY; Hsin LW; Chen HC; Lo SC; Fan JR; Chen WR; Chen HW; Chan NL; Li TK Biochem Pharmacol; 2012 May; 83(9):1208-16. PubMed ID: 22306066 [TBL] [Abstract][Full Text] [Related]
9. Exploring the Effects of Glycosylation and Etherification of the Side Chains of the Anticancer Drug Mitoxantrone. Shaul P; Steinbuch KB; Blacher E; Stein R; Fridman M ChemMedChem; 2015 Sep; 10(9):1528-38. PubMed ID: 26235383 [TBL] [Abstract][Full Text] [Related]
10. DNA recognition by two mitoxantrone analogues: influence of the hydroxyl groups. Bailly C; Routier S; Bernier JL; Waring MJ FEBS Lett; 1996 Feb; 379(3):269-72. PubMed ID: 8603704 [TBL] [Abstract][Full Text] [Related]
11. Experimental antitumor activity of the Ce(IV)-mitoxantrone complex and its interaction with deoxyribonucleic acid. Wang H; Yang P; Tian Y; Zhang Z; Zhao C J Inorg Biochem; 1997 Nov; 68(2):117-21. PubMed ID: 9336970 [TBL] [Abstract][Full Text] [Related]
12. Antineoplastic activity of mitoxantrone and its biological interactions in parental and multidrug resistant subline of P388 murine leukemia cells. Chavan S; Parekh H; Chitnis M Neoplasma; 1992; 39(1):49-57. PubMed ID: 1528304 [TBL] [Abstract][Full Text] [Related]
13. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers. Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles). Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113 [TBL] [Abstract][Full Text] [Related]
15. Synthesis, DNA-binding and cytotoxic properties of a bis(netropsin)-anthracenedione conjugate. Boitte N; Pommery N; Colson P; Houssier C; Waring MJ; Hénichart JP; Bailly C Anticancer Drug Des; 1997 Sep; 12(6):481-501. PubMed ID: 9311557 [TBL] [Abstract][Full Text] [Related]
16. Molecular basis of the low activity of antitumor anthracenediones, mitoxantrone and ametantrone, in oxygen radical generation catalyzed by NADH dehydrogenase. Enzymatic and molecular modelling studies. Tarasiuk J; Mazerski J; Tkaczyk-Gobis K; Borowski E Eur J Med Chem; 2005 Apr; 40(4):321-8. PubMed ID: 15804531 [TBL] [Abstract][Full Text] [Related]
17. Novel anthraquinone derivatives with redox-active functional groups capable of producing free radicals by metabolism: are free radicals essential for cytotoxicity? Barasch D; Zipori O; Ringel I; Ginsburg I; Samuni A; Katzhendler J Eur J Med Chem; 1999; 34(7-8):597-615. PubMed ID: 11278045 [TBL] [Abstract][Full Text] [Related]
18. Anthrapyrazole anticancer agents. Synthesis and structure-activity relationships against murine leukemias. Showalter HD; Johnson JL; Hoftiezer JM; Turner WR; Werbel LM; Leopold WR; Shillis JL; Jackson RC; Elslager EF J Med Chem; 1987 Jan; 30(1):121-31. PubMed ID: 3806589 [TBL] [Abstract][Full Text] [Related]
19. Bbr 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Beggiolin G; Crippa L; Menta E; Manzotti C; Cavalletti E; Pezzoni G; Torriani D; Randisi E; Cavagnoli R; Sala F; Giuliani FC; Spinelli S Tumori; 2001; 87(6):407-16. PubMed ID: 11989596 [TBL] [Abstract][Full Text] [Related]
20. Molecular modeling study of interaction of anthracenedione class of drug mitoxantrone and its analogs with DNA tetrameric sequences. Awasthi P; Dogra S; Awasthi LK; Barthwal R Adv Exp Med Biol; 2011; 696():385-400. PubMed ID: 21431579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]